Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Mary O'Hearn"'
1
Akademický článek
Chronic Ulcerative Herpes Simplex Virus Infection of the Vulva
Autor: Kelly Griffith-Bauer, Mary O’Hearn, Benjamin D. Ehst
Publikováno v: Case Reports in Dermatology, Vol 4, Iss 3, Pp 192-196 (2012)
Herpes simplex virus infections in HIV-infected individuals can be clinically unusual and difficult to treat due to underlying problems with cell-mediated immunity and the occurrence of antiviral resistance. Additionally, partial or incomplete restor
Externí odkaz: https://doaj.org/article/c675014e7e4c4304b25eae71e141278b
Zobrazit plný text záznamu
2
Chronic Ulcerative Herpes Simplex Virus Infection of the Vulva
Autor: Benjamin D. Ehst, Mary O'Hearn, Kelly Griffith-Bauer
Publikováno v: Case Reports in Dermatology, Vol 4, Iss 3, Pp 192-196 (2012)
Case Reports in Dermatology
Herpes simplex virus infections in HIV-infected individuals can be clinically unusual and difficult to treat due to underlying problems with cell-mediated immunity and the occurrence of antiviral resistance. Additionally, partial or incomplete restor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b35f85d23cb7acd381ff3ead8fc00342
https://doi.org/10.1159/000342953
Zobrazit plný text záznamu
3
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy*
Autor: Peter Reiss, Lucy Rowell, Damien V. Cordery, Keith Henry, Mark T. Nelson, Mary O'Hearn, Jain Chung, Anne Bertasso, Jacques Reynes, David A. Cooper, Keikawus Arastéh, Denise Guimaraes
Publikováno v: HIV Medicine. 12:31-39
Objective The aim of the study was to compare the metabolic and morphological effects of enfuvirtide plus an optimized background (OB) regimen vs. OB alone (control group) in treatment-experienced patients in the T-20 vs. Optimized Regimen Only (TORO
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a25899d5b5f6ffb0891f0ac2e2268930
https://doi.org/10.1111/j.1468-1293.2010.00845.x
Zobrazit plný text záznamu
4
Fatal Lactic Acidosis and Acute Renal Failure after Addition of Tenofovir to an Antiretroviral Regimen Containing Didanosine
Autor: Melissa D. Murphy, Sunwen Chou, Mary O'Hearn
Publikováno v: Clinical Infectious Diseases. 36:1082-1085
We describe a 49-year-old man with human immunodeficiency virus infection and stable chronic renal insufficiency who developed acute oliguric renal failure and severe lactic acidosis and who died several weeks after tenofovir was added to an antiretr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fdbcc8cbbf58c45259b8b67cb1b04fd
https://doi.org/10.1086/368313
Zobrazit plný text záznamu
6
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
Autor: Joep M. A. Lange, Jean François Delfraissy, Adriano Lazzarin, Lucille Donatacci, Keith Henry, Neil Buss, Martin Wilkinson, Bonaventura Clotet, David A. Cooper, Mary O'Hearn, Jacob Lalezari, Mark T. Nelson, Julio S. G. Montaner, Jain Chung, Jacques Reynes, Hans Jürgen Stellbrink, Daniel R. Kuritzkes, Miklos Salgo, Adeline Valentine, Peter J. Piliero, Sharon Walmsley, Calvin Cohen, Christine Katlama, Cynthia Wat, Lynn Smiley, Joseph J. Eron, Denise Guimaraes, Benoit Trottier, Keikawus Arastéh, Ralph DeMasi
Publikováno v: Journal of acquired immune deficiency syndromes (1999), 40(4), 404-412. Lippincott Williams and Wilkins
BACKGROUND The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals (n = 661) with OB
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e00bcc88e61ef05ead623d3f1fa1873
https://pure.amc.nl/en/publications/durable-efficacy-of-enfuvirtide-over-48-weeks-in-heavily-treatmentexperienced-hiv1infected-patients-in-the-t20-versus-optimized-background-regimen-only-1-and-2-clinical-trials(4eb2f353-46e3-4061-84af-7df5191c9cad).html
Zobrazit plný text záznamu
7
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
Autor: Sharon Walmsley, Peter J. Piliero, John Delehanty, Mary O'Hearn, Jacob Lalezari, Joseph J. Eron, Miklos Salgo, Jain Chung, Julio S. G. Montaner, Claude Drobnes, Calvin J. Cohen, Lucille Donatacci, Keith Henry, Daniel R. Kuritzkes, Benoit Trottier, Ralph DeMasi
Publikováno v: The New England journal of medicine. 348(22)
Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. Methods: Patients from 48 sites in the United States,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e674dd6e71eab4b0e587dbcb10a6bd93
https://pubmed.ncbi.nlm.nih.gov/14593994
Zobrazit plný text záznamu
9
Inhibition of murine suppressor cell function by progesterone
Autor: Mary O'Hearn, Daniel P. Stites
Publikováno v: Cellular Immunology. 76:340-350
The effects of progesterone on murine suppressor cell function generated in allogeneic MLCs were investigated. BALB/c splenic lymphocytes stimulated in vitro with C3H/He cells significantly suppressed the proliferative response of BALB/c lymphocytes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bba1d0cb79f7565bc64da2d79c3c35d
https://doi.org/10.1016/0008-8749(83)90377-5
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje